AGS-16C3F
- Generic Name
- AGS-16C3F
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- VC1D38AGN9
- Background
AGS 16C3F is an intravenously administered, anti-ectonucleotide pyrophosphatase/phosphodiesterase 3 (ENPP3) antibody-drug conjugate. AGS-16C3F is under investigation in clinical trial NCT02639182 (A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma).
- Associated Conditions
- -
- Associated Therapies
- -
A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
- First Posted Date
- 2015-12-24
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 133
- Registration Number
- NCT02639182
- Locations
- 🇺🇸
Site US01020, Los Angeles, California, United States
🇺🇸Site US01004, Ann Arbor, Michigan, United States
🇺🇸Site US01008, La Jolla, California, United States
A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology
- First Posted Date
- 2012-08-27
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Agensys, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT01672775
- Locations
- 🇺🇸
Site US00001 Seattle Cancer Care Alliance, Seattle, Washington, United States
🇨🇦Site CA00006 Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦Site CA00007 Jewish General Hospital, Montreal, Quebec, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.